Please login to the form below

Not currently logged in
Email:
Password:

Roche collaborates with German biotech

Kinaxo Biotechnologies has entered into a collaboration with Roche Diagnostics in Germany

Kinaxo Biotechnologies has entered into a collaboration with Roche Diagnostics in Penzberg, Germany. Under the agreement, Kinaxo's phosphoproteomics technology, PhosphoScout, will be applied to support the identification of biomarkers related to new treatment approaches based on therapeutic antibodies currently under development at Roche. Financial details of the agreement have not been disclosed.

PhosphoScout is a global, quantitative phosphoproteomics service tailored to dissect cellular signal transduction pathways and their response to drug treatment. The technology is based on proprietary mass spectrometry methods, which enable the unbiased analysis of 15,000 phosphorylation sites in a single experiment.

Dr Klaus Godl, Kinaxo's chief scientific officer, commented: "We are very pleased to partner with Roche, a world leading healthcare company. Cellular signal transmission in eukaryotic cells is mainly regulated by the reversible phosphorylation of proteins. Therefore, differential analysis of the complete cellular phosphoproteome upon drug treatment provides highly informative insights into the modes of action of targeted cancer drugs."

Kinaxo also works with Johnson & Johnson, Bayer and Boehringer Ingelheim.

21st October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics